| __timestamp | Eli Lilly and Company | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 9689000 |
| Thursday, January 1, 2015 | 6533000000 | 10431000 |
| Friday, January 1, 2016 | 6452000000 | 9618000 |
| Sunday, January 1, 2017 | 6588100000 | 12348000 |
| Monday, January 1, 2018 | 5975100000 | 28310241 |
| Tuesday, January 1, 2019 | 6213800000 | 59336147 |
| Wednesday, January 1, 2020 | 6121200000 | 159145941 |
| Friday, January 1, 2021 | 6431600000 | 199800000 |
| Saturday, January 1, 2022 | 6440400000 | 90225000 |
| Sunday, January 1, 2023 | 6941200000 | 92538000 |
| Monday, January 1, 2024 | 8593800000 |
Unveiling the hidden dimensions of data
In the world of pharmaceuticals, managing costs is as crucial as innovation. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Eli Lilly and Company and MorphoSys AG, from 2014 to 2023.
Eli Lilly, a giant in the pharmaceutical industry, consistently reported SG&A expenses averaging around $6.4 billion annually. Notably, their expenses peaked in 2023, showing a 16% increase from 2018. In contrast, MorphoSys AG, a smaller biotech firm, displayed a more volatile pattern. Their SG&A expenses surged by over 1,900% from 2014 to 2021, reflecting their aggressive expansion and investment strategies.
This comparison highlights the contrasting financial strategies of a well-established pharmaceutical leader and an ambitious biotech challenger, offering insights into their operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Incyte Corporation
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG
SG&A Efficiency Analysis: Comparing Insmed Incorporated and MorphoSys AG
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.